With a Soliris biosimilar showing up in its rearview mirror, Alexion is piling on patents for its superexpensive drug.

Should the FDA cut down drug-risk statements in TV ads? The not-surprising finding of a new agency study—short lists are easier to recall—suggests so.

After three years of work, Gilead is set to move into a new manufacturing campus in California which eventually could have 500 employees.

Our readers' nominations for best and worst M&A show dealmaking gambles can pay off—or not. Here's your chance to weigh in.

Top drugmakers and pharma's industry kept mum in the wake of Merck CEO Ken Frazier's decision to exit a Trump manufacturing panel.

Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.

Merck CEO Ken Frazier has resigned from President Trump’s Manufacturing Council and issued an indirect criticism of the president in the process.

How might Amazon blaze a trail into the pharma business? It could start with the supply chain, Goldman Sachs analysts figure.